Mediar Therapeutics is a biotechnology company developing therapeutics to halt, or even, reverse fibrosis. The platform and pipeline are based on an emerging class of novel targets, fibrotic mediators, that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar Therapeutics is in preclinical stage.